Evidence map›Paper›PMID 39590572›Full record

ReviewJournal of personalized medicine2024

Three-Dimensional Printing Technology in Drug Design and Development: Feasibility, Challenges, and Potential Applications.

Maria C Simon, Konstantinos Laios, Ioannis Nikolakakis, Theodore G Papaioannou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maria C SimonDepartment of Biomedical Engineering and Department of History of Medicine and Medical Ethics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Konstantinos LaiosDepartment of Biomedical Engineering and Department of History of Medicine and Medical Ethics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-4746-0843
Ioannis NikolakakisDepartment of Biomedical Engineering and Department of History of Medicine and Medical Ethics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Theodore G PapaioannouDepartment of Biomedical Engineering and Department of History of Medicine and Medical Ethics, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-1552-3168

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThe present investigation evaluates the impact of 3D-printing technology on the design of pharmaceutical drugs, considering the feasibility issues and problems concerning technological, pharmaceutical, and clinical matters. This paper aims to review how 3D printing can modify the traditional manufacturing of drugs with personalized medicine-therapy outcomes being individualized and optimized, hence improving patients' compliance.

methodsThe historical development of 3D printing from rapid prototyping to advanced pharmaceutical applications is discussed. A comparison is then made between traditional drug manufacturing approaches and the different techniques of 3D printing, including stereolithography, material extrusion, and binder jetting. Feasibility is assessed based on clinical trials and studies evaluating the efficacy, safety, bioavailability, and cost-effectiveness of 3D-printed drugs.

resultsCurrent evidence indicates that material selection, regulatory barriers, and scalability issues are some of the major challenges to be overcome for wider acceptance. Other matters, such as ethical issues concerning patient data privacy, the misuse of 3D-printing technology, and technical complexities related to pharmaceutical 3D printing, are discussed further. Future applications also include bioprinting and in situ printing together with their implications for personalized drug delivery, which will also be discussed.

conclusionsThis review stresses that intersectoral collaboration and the updating of regulatory frameworks are a must to overcome the barriers that confront 3D-printing applications in drug development. can could be an opportunity for innovative licensing and manufacturing techniques in pharmaceutical product development that can change the paradigm of personalized medicine through modern printing techniques.

Indexed as

additive manufacturingbiomedical engineeringpersonalized medicinethree-dimensional-printed drugsthree-dimensional printing in healthcare

Identifiers

PMID39590572
PMCPMC11595649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.